Podcasts about Hatem

Hatem Dhiab attributes today's Tesla (TSLA) earnings report as a "day of reckoning" for the EV maker. He still believes Tesla is a car company at its core, expecting a 13% drop in year-over-year deliveries to paint a nasty profit picture. Hatem says Elon Musk needs to take steps away from D.C. and back into his CEO role. He says Tesla "is a growth company that has not grown" that needs signs of turnaround in today's report.======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

Our latest episode is now live. Join host @hatem_alakeel as he sits down with the inspiring @laylakardan and @abdullaalkaabi for a powerful conversation on storytelling, creativity, and the emotion behind great art. From preserving cultural heritage to embracing authenticity in a world of curated perfection, this episode dives deep into what truly moves us.Soon available on all major streaming platforms—tune in and be inspired.#GemsOfArabia #Filmmaking #Authenticity #Storytelling #ArabVoices #CultureAndCreativity حلقتنا الأحدث أصبحت الآن متاحة! انضموا إلى المضيف @hatem_alakeel في حوار ملهم مع @laylakardan و@abdullaalkaabi، حيث يناقشون معًا قوة السرد، الإبداع، والعاطفة الكامنة وراء الفن العظيم.من الحفاظ على التراث الثقافي إلى احتضان الأصالة في عالم يفيض بالمثالية المصطنعة، تغوص هذه الحلقة في عمق ما يحرك مشاعرنا ويُلهمنا حقًا.قريبًا على جميع منصات البث الرئيسية — استمعوا واستلهموا.#جواهر_العرب #صناعة_الأفلام #الأصالة #رواية_القصص #أصوات_عربية #الثقافة_والإبداع

A discussion with Hatem Sellami, founder and CEO of both Cognira and RetSci. His career has been centered on software and modeling solutions in the retail forecasting and promotion space. He previously founded Predictix and sold it to Infor. He started his career with Retek, which was acquired by Oracle.Hatem talks about how, growing up, his family owned some retail stores, but that he didn't plan to also get into the industry. He outlines some of the key data and analytics challenges faced in the retail space. He discusses how he has learned to be more comfortable with risk over time while also explaining how he was so far ahead of the curve on the move to the cloud (the answer may not be what you'd expect!). He finishes with a discussion of how important it is for people to brainstorm in person and to build their networks over time. #analytics #datascience #ai #artificialintelligence #retail #promotions #forecasting

Hatem Dhiab says Nvidia (NVDA) is taking the steps needed to lead A.I. innovation for years to come. He argues it has been "hard to impress" Nvidia investors due to macro headwinds and uncertainties the company is tied to. Hatem believes heavy selling in the company's stock makes it more attractive of a buy than recent months.======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

I'm excited to share a special episode from the podcast, Gems of Arabia about Arab Representation in Media. The episode, hosted by WIDN alum Hatem Al Akeel, was recorded a few weeks ago at the CNN Academy in Abu Dhabi in front of a live audience of the Academy's latest cohort of budding journalists. We were joined by another WIDN alum Becky Anderson, Managed Editor of CNN Abu Dhabi and Arab News' Editor-in-Chief Faisal Abbas. This was a great conversation about breaking stereotypes, how Arab voices are represented, and the importance of re-shaping and owning our narrative on the world stage. I hope you find the conversation as insightful as I did. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, Hatem Rabeh will explain to us what are Clinical Data and also if there is a chance for you to avoid Clinical Investigations. There are also some confusion between Clinical Evaluation and Clinical Investigation. Let's clarify all this and give you the right strategies for your Medical Devices. So stay tuned.  Who is Hatem Rabeh?  Hatem Rabeh is a Medical Doctor with an MSc in Medical Engineering, specializing in clinical evaluation for medical devices.   With over 8 years of experience, he supports manufacturers in MDR compliance by preparing Clinical Evaluation Plans (CEP) and Clinical Evaluation Reports (CER) for Class I to Class III devices, including software, implants, and robotic systems.  His expertise covers literature reviews, clinical strategy, and regulatory compliance.   Hatem also shares his knowledge through online training, consulting, and LinkedIn content.  Who is Monir El Azzouzi?  Monir El Azzouzi is the founder and CEO of Easy Medical Device a Consulting firm that is supporting Medical Device manufacturers for any Quality and Regulatory affairs activities all over the world. Monir can help you to create your Quality Management System, Technical Documentation or he can also take care of your Clinical Evaluation, Clinical Investigation through his team or partners. Easy Medical Device can also become your Authorized Representative and Independent Importer Service provider for EU, UK and Switzerland.  Monir has around 16 years of experience within the Medical Device industry working for small businesses and also big corporate companies. He has now supported around 100 clients to remain compliant on the market. His passion to the Medical Device filed pushed him to create educative contents like, blog, podcast, YouTube videos, LinkedIn Lives where he invites guests who are sharing educative information to his audience. Visit easymedicaldevice.com to know more.  Link Hatem Rabeh LinkedIn: https://www.linkedin.com/in/hatem-rabeh/  Social Media to follow Monir El Azzouzi Linkedin: https://linkedin.com/in/melazzouzi Twitter: https://twitter.com/elazzouzim Pinterest: https://www.pinterest.com/easymedicaldevice Instagram: https://www.instagram.com/easymedicaldevice

This week, we were be joined by Sheikh Hatem Al-Haj - a world-renowned scholar and expert in Islamic studies. He holds a PhD in Comparative Fiqh, a Master's Degree in Islamic Law and is currently serving as a Pediatric hospitalist.Advice to the Muslim couple focuses on how to build harmony between spouses.

The latest episode is now live! Hosted by Hatem Alakeel @hatem_alakeel, this insightful discussion features two pioneering voices in Arab media: Sara Murad @sara__murad, a dynamic media personality who has built her career by challenging stereotypes and championing underrepresented stories, and Rym Saidi @rymsaidi, an influential journalist and former model who has used her platform to drive social justice and amplify marginalised communities. In this episode, they delve into the challenges they've navigated within the media industry, their evolution as entrepreneurs and leaders, and their shared mission to break barriers and create meaningful change. Listen now on all major platforms—Spotify, Apple Podcasts, YouTube Music, and more. #EmpoweringVoices #WomenInMedia #Trailblazers #CulturalBridges #PodcastLaunch #GemsOfArabia #Authenticite watch on youtube: https://youtu.be/SYBNiZKCc54

Following the devastation that's come with the LA fires, Hatem and Ayal start the year off in a different tone. On this month's episode, the guys are joined by trauma expert and certified life coach, Dr. Karen Taback, to share some healthy way to try unpacking these horrible events.Gerber Kawasaki's Resource Guide to Navigating the LA Fires:https://docs.google.com/document/d/1SPfwX0HWCJj4Kh3fWSsm2Prk-BrFQlCJ28U3Kw-0PJ8/edit?usp=sharingThe opinions voiced in this material are for general information only and are not intended to provide specific advice or recommendations for any individual. You should consult a financial advisor before making any investment decisions.

Send us a textHatem Elsayed shares his journey in the blockchain space, illustrating the vital roles of community and partnerships in Web3. The episode emphasizes investing in strong teams, creating meaningful collaborations, and the evolving trends that are shaping the future of this industry.• Exploring the significance of networking in blockchain • Hatem's journey from ambassador to COO • Importance of governance and community in blockchain projects • Overview of Advanced Blockchain AG's innovative investment strategy • Criteria for evaluating potential investment projects • Key factors for forming successful partnerships • The vital role of community engagement and feedback • Exciting narratives shaping the future of blockchain technology If you enjoyed the episode, please share it with friends and those interested in learning something new!This episode was recorded through a Descript call on December 30, 2024. Read the blog article and show notes here: https://webdrie.net/navigating-web3-investments-and-strategic-partnerships-with-hatem-elsayed-coo-of-advanced-blockchain-ag/Discover RYO: the Web3 payment solution making crypto simple and secure for everyone. Featuring an expansive ecosystem with LIFE Wallet, Global Mall, and Japan's first licensed Crypto ATM Network, RYO empowers your financial journey. Awarded 'Best Crypto Solution.'

Silvio Perrella"Ore incerte"il Saggiatorewww.ilsaggiatore.comIn Ore incerte due amanti senza patria va­gabondano in uno spazio che non ha confini. Si chiamano Hatem e Suleika e il narratore li in­contra nei pressi della Zisa di Palermo, mentre vivono in bilico tra mondi diversi, tra diorami e meridiane, con la loro Baghdad sempre pre­sente nei pensieri. Come due figure mitiche, si osservano a distanza mentre percorrono il loro viaggio, intenti a strappare attimi di passione dalle loro vite intrecciate. Ne nasce così un ro­manzo d'avventura che non conosce strade ret­tilinee ma solo soste, incontri e momenti rubati. Viaggiare e raccontare sono una fuga co­stante dall'ordinario, «un'ora incerta» che si muove tra albe e tramonti, tra luci e ombre, tra gioia e dolore. I luoghi stessi prendono vita alla stregua di personaggi intravisti in una lanterna magica: spiagge che sprofondano nell'infinito, fari che illuminano sogni e ricordi, porti dove il mare e la terra si mescolano fino a confondersi. Silvio Perrella dà vita a una danza di parole e immagini che ha il ritmo indiavolato di un bolero, dove Hatem e Suleika si trasformano nel simbolo di un amore che sfida il tempo e lo spazio, alla costante ricerca di un nuovo oriz­zonte da attraversare insieme.Silvio Perrella (Palermo, 1959), scritto­re, ha pubblicato tra gli altri Fino a Salgareda (2003), Giunapoli (2006), In fondo al mondo (2014), Doppio scatto (2015, nuova edizione 2024), Petraio (2021), Metronomi sotto i tavoli (2024). Ha curato il Meridiano delle opere di Raffaele La Capria e con lui ha scritto a quattro mani Di terra e mare (2018). Collabora con Rai Radio 3 e con la Radio svizzera italiana.IL POSTO DELLE PAROLEascoltare fa pensarewww.ilpostodelleparole.itDiventa un supporter di questo podcast: https://www.spreaker.com/podcast/il-posto-delle-parole--1487855/support.

On the final episode of 2024, managing partners Hatem and Ayal reminisce on the past 12 months and discuss what they got right as well as what they got wrong. Have a wonderful holiday season, and we look forward to bringing you more Future Money in the new year!The opinions voiced in this material are for general information only and are not intended to provide specific advice or recommendations for any individual. You should consult a financial advisor before making any investment decisions.

 In the first interview we talked to James Hatem. Talking to James was like talking with someone we've known forever. He told us about learning guitar at the age of 11, his Billy Joel obsession, and how listening to music can be practice too!  In the second part of the interview, we talk with Kevin Gordon about his health scare that almost stopped his album “ The In Between “ (released September 13, 2024) from being released, his poetry background, and some great advice for new artists.   Check them out here:  James Hatem  Website: Jameshatem.com  Facebook: James Hatem  IG: Jameshatemmusic  TikTok: Jameshatemmusic  YouTube: James Hatem    Kevin Gordon:  Website: https://kg.kevingordon.net/  Instagram :KevinGordon  YouTube: Kevingordonmusic  BandCamp: Kevingordon  

This Week's Guests: Just Noam and Hatem discuss things Episode 341 "Rethink Production presents "Live From America Podcast" - a weekly show that combines political commentary with humor. Hosted by the comedy cellar owner Noam Dworman and producer Hatem Gabr, the show features expert guests discussing news, culture, and politics with a blend of knowledge and laughter. Follow Live From America YouTube @livefromamericapodcast twitter.com/AmericasPodcast www.LiveFromAmericaPodcast.com LiveFromAmericapodcast@gmail.com Follow Hatem Twitter.com/HatemNYC Instagram.com/hatemnyc/ Follow Noam Twitter.com/noam_dworman #BidenPardon #Pardon #LivefromAmericaPodcast

Special Guest: Ace HatemProducer: Ryan T. HuskAudio Engineer: Scott JensenExecutive Producers:Jason OkunAssociate Producers:Homer Frizzell Dr. Ann Marie Segal  Eve England Yvette Blackmon-Tom TJ Jackson-BeyTitus MohlerDr. Mohamed Noor  Tierney C. Dieckmann  Anil O. Polat Joe BalsarottiMike GuDr. Stephanie BakerCarrie SchwentFaith HowellEdward Foltz AKA Crewman guyMai, Live From TokyoMatt BoardmanChris McGeeJustin WeirJake BarrettHenry UngerAllyson Leach-HeidJulie ManasfiMarsha "Classic" SchreierJed ThompsonDr. Susan V. GrunerGlenn IversonDave GregoryTim BaumChris SternetGreg K. WickstromSpecial Thanks to Malissa LongoEvery week, we rewatch an episode of The Next Generation, relive and review it. Join us!Rewatch TNG every week and get in on the discussion - we'd love to have you!If you enjoy our content please leave us a five star rating and comment/review.Support and join the community here:https://www.patreon.com/The7thRuleWatch the episodes with full video here:https://www.youtube.com/c/The7thRuleSocial media:https://twitter.com/7thRulehttps://www.facebook.com/The7thRule/https://www.facebook.com/groups/The7thRuleGet cool T7R merchandise here:https://the-7th-rule.creator-spring.com/Malissa Longo creates fun and functional Star Trek art at:https://theintrovertedrepublic.com/Get radical Trek swag at Ryan's online store here: https://star-trek-and-chill.myshopify.com/We continue The 7th Rule journey without our friend, our brother, Aron Eisenberg.He is still with us in spirit, in stories, in laughter, and in memories, and the show must go on.

Pour le 11ème et dernier épisode d'Amour Jungle, Ben Mazué, Fanny Sidney, Élise Baudouin et Jean-Baptiste Toussaint aka Tales From The Click relisent leurs courriers coup de cœur.Au programme :- Relectures croisées des courriers préférés de Fanny, Élise & JB- La thématique des violences conjugales avec la Dr Hatem de La Maison des Femmes & une chanson inédite sur ce thème- La chanson inédite "Amour Jungle" par Vincha pour finir la saisonAmour Jungle, une émission en 11 épisodes inspirée par Maud Ventura et écrite par Ben Mazué et Fanny Sidney

Kathy Hatem, Senior Communications Advisor, Enough Is Enough. Enough Is Enough, a national non-profit organization that has been fighting to make the internet safer for children and families since 1994, brings her passion for child advocacy and safety full circle in today's digital age, raising public awareness about the harms of child predators, sex trafficking, social media, cyberbullying, internet pornography and other dangers. Will the Candidates Step Up to Protect America's Youth from Online Child Exploitation

What kind of risk taker are you ? Imagine being presented with a choice: receive $100 with 100% certainty or take a chance on $200 with 50% probability. Do you dare to take a leap of faith, or do you play it safe? The answer may reveal more than you think.Risk aversion is ingrained in our human heritage. Our ancestors who took excessive risks did not live long enough to pass on their genes to the next generation. Yet risk taking is the driving force behind societal progress. Whether you are a portfolio manager, a trader or an entrepreneur, managing risk is an integral part of the human experience. In this episode of 2050 Investors, host Kokou Agbo-Bloua takes a closer look at risk and its role in the financial markets. Kokou explores traditional risk management models such as Value at Risk, volatility and heteroskedasticity (volatility of volatility) and explores the interplay between Main Street and Wall Street. Later in the episode, Kokou sits down with Hatem Mustapha, Co-Head of Global Markets, to discuss the ins and outs of managing risk in global market activities. They examine different risk management models, their pros and cons, and the importance of setting an absolute level of risk consistent with one's capital and ability to absorb losses, while taking smart risks with a favourable risk/return profile. Drawing on over 30 years of experience in global markets, Hatem also discusses the biggest mistakes investors make when managing risk, the role of artificial intelligence (AI) and the world of 'unknown unknowns'.About this showWelcome to 2050 Investors, your monthly guide to understanding the intricate connections between finance, globalisation, and ESG.Join host Kokou Agbo-Bloua, Head of Economics, Cross-Asset & Quant Research at Societe Generale, for an exploration of the economic and market megatrends shaping the present and future, and how these trends might influence our progress to meeting 2050's challenging global sustainability targets.In each episode, Kokou deep-dives into the events impacting the economy, financial markets, the planet, and society. Through a magical blend of personal anecdotes, in-depth research and narratives overlaid with music, sound effects, and pop culture references, there's certainly something for everyone.Kokou also interviews industry-leading experts, personalities, entrepreneurs and even Nobel prize winners! You will learn from the best on a wide range of subjects on current affairs, market shifts, and economic developments.If you like 2050 Investors, please leave a five-star review on Apple Podcasts or Spotify. Your support will help us spread the word and reach new audiences. If you're seeking a brief and entertaining overview of market-related topics and their business and societal implications, subscribe now to stay informed!Previous episodes of 2050 Investors have explored ESG, climate change, AI, greenflation, globalization, plastic pollution, food, healthcare, biodiversity and more.CreditsPresenter & Writer: Kokou Agbo-Bloua. Editors: Vincent Nickelsen, Jovaney Ashman, Linda Isker & Jennifer Krumm. Production Designer: Emmanuel Minelle, Radio K7 Creative. Executive Producer : Fanny Giniès. Sound Director: Marc Valenduc. Music: Rone. Graphic Design: Cédric Cazaly.Whilst the following podcast discusses the financial markets, it does not recommend any particular investment decision. If you are unsure of the merits of any investment decision, please seek professional advice.Hosted by Ausha. See ausha.co/privacy-policy for more information.

INTERVIEW: Gemella Reynolds-Hatem from Te Rōpū Māori on Te Wiki o Te Reo Māori activities by Zac Hoffman on Radio One 91FM Dunedin

In this episode Blake continues his conversation with Richard Hatem (Mothman Prophecies, Titans, Under Siege 2) about his new podcast.  Karen was away during this episode but will be back next week.Additional Links:Spiricom via Encyclopedia.comSpiricom – by Kenny Biddle via Skeptical InquirerRecording of a Spiricom Session (YouTube)The Mothman Prophecies (amz affiliate link)Titans (amz affiliate link)Miracles (amz affiliate link - to DVD)This episode brought to you by Factor Meals - use our link or code MonsterTalk50 to 50% off your first order!Become a supporter of this podcast: https://www.spreaker.com/podcast/monstertalk--6267523/support.

Shawqi Hatem: From Gaza to South Africa – A story of survival and hope by Radio Islam

In this episode Blake talks with Richard Hatem (Mothman Prophecies, Titans, Under Siege 2) about his new podcast.Additional Links:Spiricom via Encyclopedia.comSpiricom - by Kenny Biddle via Skeptical InquirerRecording of a Spiricom Session (YouTube)Become a supporter of this podcast: https://www.spreaker.com/podcast/monstertalk--6267523/support.

In this episode of JCO Article Insights, Dr. Giselle de Souza Carvalho interviews Dr. Hatem Azim and Dr. Ann partridge on their JCO article “Fertility Preservation and Assisted Reproduction in Patients With Breast Cancer Interrupting Adjuvant Endocrine Therapy to Attempt Pregnancy,” TRANSCRIPT Giselle Carvalho: Welcome to the JCO Article Insights episode for the August issue of the Journal of Clinical Oncology. This is Giselle Carvalho, your host. I'm a Medical Oncologist in Brazil focusing on breast cancer and melanoma skin cancers, and one of the ASCO editorial fellows at JCO this year. Today, I will have the opportunity to interview Dr. Hatem Azim and Dr. Ann Partridge, two of the authors of the POSITIVE trial. We will be discussing their trial on “Fertility Preservation and Assisted Reproduction in Patients With Breast Cancer Interrupting Adjuvant Endocrine Therapy to Attempt Pregnancy,” which was published in May this year.  Hello, Dr. Azim and Dr. Partridge. Welcome to our podcast. Dr. Ann Partridge: Hi. Thanks. Dr. Hatem Azim: Hello. Giselle Carvalho: So, beginning with our interview for breast cancer survivors, in addition to the treatment itself, aging is one of the major contributors to infertility. The optimal duration of adjuvant endocrine therapy in patients with hormone positive early breast cancer ranges from five to ten years, depending on patient and tumor characteristics. This time interval can be critical for women who wish to attempt pregnancy. One of the main concerns in daily breast cancer oncology practice is whether breast cancer recurrence rates are increased either by temporary interruption of endocrine therapy for pregnancy or by the use of assisted reproductive technologies. Dr. Azim, what about assisted reproductive technology is worrisome regarding breast cancer outcomes? And how do the POSITIVE study results address the concern about worsening breast cancer outcomes either with assisted reproductive technology or endocrine therapy interruption? Dr. Hatem Azim: So, in the primary analysis of the POSITIVE trial, we tried to address one of these questions, whether temporary interruption with endocrine therapy affects breast cancer outcome. And what we found was that interruption did not appear to have a detrimental impact at the median follow up of 41 months. So in the current manuscript, we addressed the second question, whether assisted production of fertility preservation has an impact as well on breast cancer outcome. And we did not find any worsening of outcomes in patients who underwent these procedures compared to those who had a spontaneous pregnancy. Of course, we have relatively short follow up, but at least the outcomes at the median follow up of around 3 to 4 years appears to be reassuring. Giselle Carvalho: I see. Thank you. These are really important outcomes regarding premenopausal patients. So, moving on, results from your study show that after 24 months, 80% of women under 35 years old had at least one successful pregnancy, while the same was true for 50% of women aged 40 to 42. These results are particularly impressive considering that over 60% of women over 35 had undergone chemotherapy.  Dr. Partridge, other than age, what factors did you find were associated with a successful pregnancy?  Dr. Ann Partridge: Yeah. The biggest factor, other than age, that was associated with successful live birth pregnancy was use of assisted reproductive technologies. So either having gone through IVF prior to diagnosis and banking eggs or embryos prior to diagnosis and then using them during the study, for undergoing stimulation of the ovaries during the study and then using it during the study. And that's what we also looked at in this most recent analysis of the initial POSITIVE data.  Giselle Carvalho: I see. Thank you. The group of patients who underwent embryo oocyte cryopreservation at diagnosis were more likely to be nulliparous and treated with chemotherapy. Presumably these represent the patient group most afraid they will be infertile, as they would be receiving chemotherapy, and most desirous of pregnancy, as they had not yet had any children. Fertility preservation techniques are expensive and not easily available for all patients, particularly in less wealthy countries. Is there any group of your breast cancer patients with a high enough likelihood of pregnancy without assisted reproductive technology that you would not recommend this?  Dr. Ann Partridge: Sure. So we are so glad to have assisted reproductive technologies available in many places, but as you know, they're not available everywhere. And even where they're available for some people, it's either inaccessible for a number of reasons or it doesn't feel right emotionally or ethically. And then finally, sometimes people need fairly quick treatment and they just don't have the time, even though we don't think there are long delays. And so we do and are able to know who can get pregnant after standard chemotherapy. Not perfectly, but we can give estimates. And the gestalt is, the younger a woman is, the less likely she is to become amenorrheic and the associated infertile, although it's not a perfect match in terms of amenorrhea being a surrogate. And then there are particular chemotherapy regimens that are more gonadotoxic than others. The more cyclophosphamide, for example, or alkylating agent, the more anthracycline, the higher the likelihood generally of causing at least amenorrhea and likely infertility. The huge caveat there is that for some of our newer therapies, we have no good information about how they might impact on menstrual status, let alone the actual rates of fertility. So we need to collect those data. But certainly, if someone's very young, they're going to get four cycles of TC or they have inflammatory breast cancer, we often take kind of a let the chips fall where they may approach, because they just aren't able to access it and we'll often do something like ovarian suppression through the chemotherapy to help support them and hope that it improves their menstrual functioning in the long run and/or fertility. Giselle Carvalho: Thank you for your insight. So you found that pregnancy incidence over time differed by age group, although incidence of menstrual recovery over time was similar across all age groups, which I conclude that menstrual recovery does not translate into fertility. The addition of gonadotropin releasing hormone analogs to chemotherapy was not associated with time to pregnancy. However, of course, such use was not randomized.  Dr. Azim, if assisted reproductive technology is not available to patients for reasons such as socioeconomic factors, would you recommend using GnRH analogs with chemotherapy for the purpose of fertility preservation?  Dr. Hatem Azim: Yes. The short answer is yes. Of course, POSITIVE study was not designed to address the question around GnRH analogs, but we do have several randomized studies and meta analyses that have shown clearly that the use of GnRH analogs with chemotherapy reduce the risk of premature ovarian insufficiency. And subgroup analysis of some of these studies have shown a trend towards higher pregnancy rates as well. So, of course, if a patient does not have access to assist reproductive technology, GnRH analogs in combination with chemotherapy represent a very good alternative.  Giselle Carvalho: I see. Thank you. Thank you for your response. At enrollment, 93.2% of women on POSITIVE trial had stage 1 or 2 disease and 66% had no negative disease. Therefore, one possible bias is that investigators might have been more comfortable with temporarily interrupting endocrine therapy if the risk of relapse was low. Dr. Partridge, what recommendations would you have for women with stage three hormone receptor positive breast cancer who desire to attempt pregnancy? Dr. Ann Partridge: Yeah, thank you. That's a really good question. It comes up in our tumor boards and discussions about patient care all the time, and I think, as you know, only a small proportion, about 6%, had stage 3 disease. Those patients are at higher risk of recurrence by nature of their stage. Not that all stage 3 are created equal, because, of course, if someone had a complete pathologic response to preoperative therapy and their stage 3 disease at diagnosis went to a PCR, then that person may have even better outcomes in the long run than someone who had postoperative treatment, and we don't know their likelihood even with stage 1 or 2 disease. But someone that you're concerned about their risk of recurrence, they still remain at risk of recurrence. And while we do not think, based on the POSITIVE data and all the data that we've had from retrospective studies and other data sets collected for other reasons, that a pregnancy would worsen their outcome, we certainly don't believe that a pregnancy at this point in time will dramatically improve their outcome or as a treatment for breast cancer. That's when I have a heart to heart conversation with the patient, really acknowledging they still remain at high risk. And most of my colleagues tend to want the patient to get more endocrine therapy into their system before they take a break. We've kind of discussed this, and we want someone to get more like at least three to five years. That may be a little bit paternalistic, because, as we know, taking the break for people with a little lower risk didn't seem to worsen outcomes. Maybe it's fine. I don't know that a break at five years is any better than a break at two years. I don't know. Hatem, how do you handle this in your practice?   Dr. Hatem Azim: Well, I completely agree with you, Ann. I mean, it's very much decided on a patient by patient basis. The level of uncertainty that some patients accept to take is not necessarily like others. And sometimes we as physicians, we adopt this. I agree with this paternalistic approach. Nevertheless, it's very important for the patient who is 32, is not necessarily counseled like the patient who's 39, and her acceptance and the feasibility of waiting a bit longer as well in order to attempt pregnancy - the success of pregnancy afterwards is not necessarily the same. So I'm not sure we could adapt a one size fits all approach here. And I do not necessarily tend to factor much the elements around the stage. I think my point to patients is usually, well, you do have give and take this amount of risk of relapse, for example, and whether we accept to take such, what we could refer to as relatively unconventional approach of temporary interrupting endocrine therapy, and when we are comfortable to go ahead with this journey, depending on the feasibility of getting pregnant afterwards as well. So, yeah, I completely agree. It's very customized, based on and tailored according to the patients' situation. Giselle Carvalho: Thank you. I really appreciate your response to this. So, moving forward, tamoxifen alone was the most commonly prescribed endocrine therapy, followed by tamoxifen plus ovarian function suppression. The latter was preferred over aromatase inhibitors ovarian function suppression in the selected population. Endocrine therapy prescription changed in the second half of the recruitment period after July 2017 across all continents, likely due to the results of the SOFT and TEXT trials. It demonstrated absolute improvements in all disease outcomes by escalating endocrine therapy, which was more clinically meaningful in patients with high risk disease. Dr. Azim, how do you imagine this change could impact positive outcomes? Dr. Hatem Azim: Honestly, I'm not necessarily sure that it impacts significantly the way you interpret the data and the way we counsel our patients. So, in our study, some 50% of patients received GnRH analogs and around 15% received AI. And most of the patients, I would say, were recruited in the second half of the study after we had the results from, for example, SOFT and TEXT. Furthermore, as we alluded to earlier, we had 60% of patients who received chemo. So most of our patients had a stage 1 and 2 disease in which you would argue that the absolute difference between the different hormonal therapy options is not necessarily massive. Whether or not this would impact much, I'm not sure. I think the main counseling recommendations would apply, that patients who receive endocrine therapy would be asked to interrupt it for at least three months and then they attempt pregnancy afterwards. I don't know what you think, Anne, but I'm not sure that if we have more patients, and this is pretty much the case now, we have more patients treated with AI. I tend to do this a lot, especially if I'm thinking of interrupting, so I think I'm giving them maybe the best option first. I'm not sure this is necessarily, I mean, affecting me much, while interpreting that it does not appear that temporary interruption on the short term has an impact. Dr. Ann Partridge: I completely agree with your strategy. Depending on the patient and their tolerance, if they have enough risk to warrant ovarian suppression with AI or tamoxifen, of course I recommend that. And yet, at the same time, I agree with you in this group that was in POSITIVE, I think the groups are relatively low enough risk. Although 40% had no positive disease, the majority got chemo, so they weren't that low risk. And so I think over time, these kinds of patients are more and more going to get ovarian suppression. I'm doing that more in my practice as tolerated. And I hope that all that means is that their breast cancer outcomes will be better independent of a pregnancy. Giselle Carvalho: And on the topic of women with higher risk disease, CDK4/6 inhibitors are now used in the high risk adjuvant setting. How do you envision this impacting fertility? Dr. Hatem Azim: Well, this is a very good question. Of course, this is something, this is an area of research that we have to address. Some analysis from some of the adjuvant studies, for example, the PENELOPE-B, I think they reported on some of the results of their study in which they were evaluating palbociclib in the adjuvant setting and did not appear that there was significant differences in terms of the level of estradiol levels and FSH and anti-Müllerian hormone, for example. I think these were the parameters that were evaluated in this study. So, of course, more information. Of course, palb is not the CDK4/6 inhibitor approved in the adjuvant setting. So we need more information as well about the other CDK4/6 inhibitors and longer follow-up.  In my view from a counseling perspective, I think maybe you would have a certain level of uncertainty regarding whether or not this could have a mental impact on fertility. But the concept as well of possibly proposing a temporary interruption as we adopted in POSITIVE, would still apply. These patients would be treated as well, often, because if they are receiving CDK4/6 inhibitors in the adjuvant setting, it means that they have a high stage disease, so often they will be treated as well with GnRH analogs. I would counsel them pretty much the same, acknowledging a certain level of uncertainty regarding the data we have today on CDK4/6 inhibitors. Dr. Ann Partridge: Yeah, if they got a full course, they would generally be further out than many people on POSITIVE, because we treat with, for example, the abemaciclib for two years and then you want to wash out and things like that. In POSITIVE, the average was two years. And so you'd expect people of higher risk to be a little further out, which I think would make everybody a little more comfortable too, because someone who's very high risk, you'd worry about very early bad recurrence, too. Giselle Carvalho: Yeah. Thank you. So, Dr. Partridge, regarding adherence to endocrine therapy resumption after the two year break, what was the percentage of patients who resumed treatment and which strategies would you suggest to increase adherence in this case? Dr. Ann Partridge: That's a really great question. In the study, it was well over 70%, which is actually higher than you see in the general population of breast cancer survivors, especially young women. So in some cases, and I can tell you anecdotally, I experienced in my clinic that patients were more likely to start and take their endocrine therapy when they had the promise of the POSITIVE trial, to take a break to have a baby, because some of them don't want to start it, let alone stay on it, if they're told they have to take a full five to ten years. So it actually promoted adherence, ironically. And then for the people who got back on in the real world, the data suggests that by four years, somewhere close to half to 30% to half are no longer taking it. And so in POSITIVE it was, I think, 74% got back on, and that was only at the time point cut off when we did the initial primary data report. And of course more people will have gone back on because some people were still having babies and in the middle of things. And so I think that it's not as much of an issue with POSITIVE. In part, these are very compliant people, right? They're participating in a clinical trial to share the data with the rest of the world. They could have gotten pregnant on their own and they want to do it with their doctors. And so I think this is a little bit of a different group, but it was very reassuring to see that most people got on hormonal therapy after their interruption. Giselle Carvalho: And recurrence of hormone receptor positive breast cancer may occur late. How long do you plan to follow patients enrolled in the POSITIVE trial? Dr. Ann Partridge: So our plan is to follow them for at least 10 years. And it's interesting because we're starting to get close to that. We started enrollment in 2015, so I saw someone earlier this week who will have her 10 year mark next year because she got on in 2015. And that's very exciting. Obviously, it would be great to follow them even longer because ER positive breast cancer can recur many years later. But I do think that we feel as though at least 10 years will give us a good, very evidence-based feeling about the safety. Giselle Carvalho: Thank you. Thanks for sharing. With enrollment occurring at 116 institutions in 20 countries across four continents, this representation of different races and ethnicities provides strength to support this recommendation for this group of patients worldwide. Dr. Azim, what are your hopes for future analysis from this study and what future research in the area are you planning or would like to see performed?  Dr. Hatem Azim: So Ann mentioned, of course, it would be crucial to conduct the long term follow up of these patients, and provide more reassuring evidence on the safety of this approach of adjuvant endocrine therapy. So this is something we're really looking forward to. Other analysis that we are working on is the breastfeeding analysis. So looking at patients who underwent breastfeeding and how far the feasibility of this approach, obviously, but how far as well this had an impact on their breast cancer outcome. So this is something that hopefully we are going to report on soon, expected end of this year. As well, we are working on evaluating, we had a large translation research program within POSITIVE, addressing several questions, including the evolution of ovarian function parameters over time and the ovarian reserve. Also, we are working on reporting on this information. We hope that this could happen maybe in the coming year. Giselle Carvalho: Great. And finally, what advice do you give young women in your clinic who have been diagnosed with early stage hormone positive breast cancer and who are hoping to attempt pregnancy. Dr. Hatem Azim: We address these kinds of questions relatively early in their treatments and often they are very much concerned about their chance of future fertility. Usually early on, for example, before going for chemo and so on, I just share the information that this is something that we certainly could discuss and certainly there are the possibility that we could consider in the future that it's not a ‘no go' at least. And definitely it's something that we could work on once treatment is completed and recover from the adverse events of therapy. And because throughout the journey of treatments as well, women's wishes evolve over time and their perception of their pregnancy project as well evolve and change over time. So I think it's important to acknowledge, in my view, it's very important to acknowledge that this is feasible, this is possible, and because this as well provides an important psychological boost for them. And then as the patient comes over for their follow up after therapy and so on, start understanding, getting a little bit deeper into these kind of questions regarding feasibility, timing. If they are ER positive, then if it's okay to interrupt, not to interrupt, to explain a bit better and to consider a bit better regarding what kind of risk we're talking about. Articulating better, what do we mean by risk? So that sometimes you have a patient that is willing to accept a 10% risk, although others 1% risk for them represent a major threat. Also, it matters nulliparous versus a patient who already has two or three kids. So I think I tend to go a bit more granular in this kind of information as patients are out of chemo and on hormonal therapy and start addressing these matters. But I think it's important early on to share the information that nowadays we do have sufficient information not to discourage women who would like to have a pregnancy in the future. Giselle Carvalho: Thank you. Thank you. Dr. Partridge, would you like to add some final comments on this? Dr. Ann Partridge: Yeah, I think this is just such an important issue for our young breast cancer survivors and cancer survivors diagnosed at a young age, regardless of the type of cancer. So I think paying attention to this at diagnosis and through their survivorship is critical, both for their thriving in survivorship as well as for their long term health and cancer outcomes. Getting back to that adherence issue, people, if they're unhappy, won't do all the right things for themselves, sometimes medically and emotionally. And we know that infertility can be associated with long term distress for patients with and without cancer. So we need to pay attention to this and I'm really happy that ASCO is doing a podcast on this and I'm really happy that JCO is doing a podcast on this.  Giselle Carvalho: Thank you. I really would like to thank you both, Dr. Azim and Dr. Partridge for attending this interview. This is Giselle Carvalho. Thank you for listening to JCO Article Insights. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows asco.org/podcast. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.  Dr. Azim Employment Company name: Pierre Fabre, EMERGENCE THERAPEUTICS Stock and Other Ownership Interests Company name: Innate Pharma, Diaacurate Travel, Accommodations, Expenses Company name: Novartis Dr. Partridge Research Funding Company name: Novartis Patents, Royalties, Other Intellectual Property Company name: UpToDate    

Hatem Abudayyeh, national chair of the Chicago-based U.S. Palestinian Community Network advocacy group, joins John Williams to talk about a federal judge ruling that it will not force the city of Chicago to alter the path offered to DNC protesters. Hatem tells John why they are disappointed with the ruling and why they will be appealing.

Hatem Abudayyeh, national chair of the Chicago-based U.S. Palestinian Community Network advocacy group, joins John Williams to talk about a federal judge ruling that it will not force the city of Chicago to alter the path offered to DNC protesters. Hatem tells John why they are disappointed with the ruling and why they will be appealing.

Hatem Abudayyeh, national chair of the Chicago-based U.S. Palestinian Community Network advocacy group, joins John Williams to talk about a federal judge ruling that it will not force the city of Chicago to alter the path offered to DNC protesters. Hatem tells John why they are disappointed with the ruling and why they will be appealing.

Next week, from Aug. 19-22, the much anticipated Democratic National Convention will kick off in Chicago, and protestors from Chicago and around the country are preparing to descend on the DNC in full force. For organizers and the over 200 organizations that comprise the Coalition to March on the DNC, Palestine is at the top of the agenda—and the city of Chicago seems determined to keep protesters from making their dissent known to the nation and the world. For months, march organizers have been locked in a legal battle with the city over protest permits and approved march routes, but Hatem Abudayyeh, a spokesperson for the Coalition to March on the DNC and national chair of the US Palestinian Community Network, says the protests are happening one way or another. What is the current plan for the DNC protests? What should protestors, DNC-goers, and Chicago residents expect during the week of the DNC? The Real News speaks with Abudayyeh to get an insider perspective and the latest updates on the coalition's plans to march on the DNC.Read the transcript of this podcast here. Studio Production: Maximillian AlvarezPost-Production: Alina NehlichHelp us continue producing radically independent news and in-depth analysis by following us and becoming a monthly sustainer.Sign up for our newsletterLike us on FacebookFollow us on TwitterDonate to support this podcast

In this episode of the Blood Brothers Podcast, Dilly Hussain speaks with the prominent Palestinian American scholar of decolonisation and Islamic theology, and the co-founder of Zaytuna College, Dr. Hatem Bazian.    Topics of discussion include:  What have pro-Palestine student encampments achieved?  Institutional decolonialism and decolonialism in reality. ⁠ Pride month and LGBTQ support for Palestine, and support for Palestine at Glastonbury Festival. Is the mainstreaming of the Palestinian cause a positive development?  Who are the real allies and gatekeepers of the Palestinian cause? Palestinians? Arabs? Muslims? Socialists? Anti-war left? ⁠U.S. hegemony in the Muslim world and American Muslim patriotism. Is there a conflict between the two?  Gulf normalisation with Israel, Arab/Muslim world's inaction over Gaza, and boycotting. ⁠Muslim leadership in the west calling for normalisation with Israel via “Abrahamic” interfaith.  FOLLOW 5PILLARS ON:    Website: https://5pillarsuk.com YouTube: https://youtube.com/@5Pillars Facebook: https://www.facebook.com/5pillarsuk Instagram: https://www.instagram.com/5pillarsnews Twitter: https://twitter.com/5Pillarsuk Telegram: https://t.me/s/news5Pillars TikTok: https://www.tiktok.com/@5pillarsnews

On this episode, we are joined by Dr. Hatem Al-Haj who talks to us about Prayer: the second pillar of Islam. Dr. Hatem breaks down the beauties and intricacies of the prayer, and reflects on how he started to pursue knowledge of Islam. We also discuss the important of having good manners and the etiquette of online discussions. --- Send in a voice message: https://podcasters.spotify.com/pod/show/relayislam/message

Etude des salaires de la tech en 2024, c'est icihttps://theproductcrew.io/ressources/salaires-de-la-tech-2024/Bienvenue dans cet épisode de Product Squad, le podcast où nous explorons les coulisses du Product Management et des tendances technologiques. Aujourd'hui, nous accueillons Pierre, un ancien financier reconverti en Product Manager et cofondateur de la communauté TPC, qui rassemble plus de 10 000 professionnels du product design, de la tech et des données.Au programme de cet épisode, nous discutons des méthodes de voyage de Pierre, des défis et opportunités liés à l'intégration de l'IA dans les produits, et de l'impact émotionnel et professionnel de l'IA sur le contenu artistique. Nous abordons également des sujets cruciaux comme l'inégalité salariale entre hommes et femmes dans le secteur technologique et des initiatives visant à combler cet écart. Enfin, nous explorerons les tendances actuelles du marché du Product Management et les outils innovants qui révolutionnent notre façon de travailler.Rejoignez Victor, Axel, Anna et notre invité Pierre pour un échange riche en insights et en discussions passionnantes. Bonne écoute à tous !(03:16) Reconversion finance à TPC, tendances marché produit.(07:15) Étude : 3200 répondants, profils divers, résultats intéressants.(10:20) Intérêt pour l'IA dans le quotidien professionnel.(22:29) Spotify et GenAI.(23:34) Impact de Spotify sur la musique(29:10) Préparation vacances & itinéraire personnalisé

Everyone's at maximum freakout in the leadup to World Happiness Dance, whatever that is, and nobody can figure out who's going with who -- especially with the addition of two new students, Delia and Cory, shaking up the social circles. Adding to the confusion: We're getting Brian's inner monologue instead of Angela's! What's going on???? And why is Graham so determined to wallpaper the bedroom instead of dealing with those cooking classes?Helping me break it all down is Trevor McMahan from the YouTube channel Media Processing; as well as Sharon Johnson and Susan Lambert Hatem from the podcast 80s TV Ladies.Also: We'll be taking a two-week break from posting new episodes while I travel to Toronto for Pride (join me at the Toronto Public Library on June 12!) and we'll be back with regular episodes on June 17.

أحمد حاتم ممثل مصري، اشتهر بأدواره في أفلام عديدة مثل “أوقات فراغ”، و”الهرم الرابع”، ومسلسل “أنا وهي”. في البرنامج، يقدم لنا أحمد لمحة خاصة عن حياته خارج الشاشة، منذ أيامه الأولى في التمثيل، إلى تجاربه مع الحب والطلاق، وما تعنيه الأبوة بالنسبة له. تابعونا لنتعرف على الانسان خلف لقب الممثل الشهير أحمد حاتم.

Don't worry, market corrections are normal! On this episode of Future Money, Hatem and Ayal explain why we shouldn't be too worried by recent declines. The guys also touch on rate cuts, Q1 earnings reports, and more!The opinions voiced in this material are for general information only and are not intended to provide specific advice or recommendations for any individual. You should consult a financial advisor before making any investment decisions.

Hatem Mekky, Director of Engineering for the City of Fishers...and his new Assistant Director Brad Pease, provide on update on road construction in this podcast.

Hatem Alakeel is an award-winning Saudi designer, fashion entrepreneur and podcast host. He has designed for global icons including Mattel's Barbie, Evian, Lexus, Fairmont, Raffles, and the Ritz Carlton among others, and he was among the first regional artists to create and celebrate Saudi traditions. With his first company, Toby Hatem Alakeel, Hatem brought the traditional thobe into the luxury fashion world, with displays at Harvey Nichols, Saks Fifth Avenue, and Boutique 1. Today, he runs Authenticite, a consulting and creative production agency connecting creators and brands who want to understand Saudi culture. He also continues developing content with his editorial pieces showcasing Saudi artists on his website, and through his podcast, Gems of Arabia. Learn more about your ad choices. Visit megaphone.fm/adchoices

After a surge in rates and recent changes in legislation, everyone wants to know the most effective ways to navigate LA's real estate market. This week, Hatem and Ayal sit down with Buying Beverly Hills star Jon Grauman to ask the questions that are on everyone's mind.

After years of anticipation, Hatem and Ayal finally received their Apple Vision Pros! Check in with the guys to find out how they like their new tech tools, however, their review may surprise you…The opinions voiced in this material are for general information only and are not intended to provide specific advice or recommendations for any individual. You should consult a financial advisor before making any investment decisions.

Hailing from Cairo, Chiati has emerged as a multi-instrumentalist performer in the Middle East. His music seamlessly blends emotive house rhythms with pop vocals, showcasing his versatility both in the studio and on stage. His seraphic vocals intertwined with harmonious melodies, honed through years of mastering various instruments such as the guitar and keys, have earned him various gigs at venues like Shorelines, XCHANGE Cairo, Glasshouse, and Nacelle's Sandbox, among others. Collaborating with artists like Juno and Naila Marie, Chiato has graced the stage alongside renowned acts such as &ME, Damian Lazarus, Henrik Schwarz, me, DJ Tennis and more. Recently, he unveiled his latest work on Noise Records' "Genesis, منش'' with his eclectic house single ‘In the Dark.' This week, Hatem presents us with a special set: a live gig by Chiati performed at Nacelle's Sandbox Festival in 2023. In this Select, Chiati performs an hour-long set guiding his listeners through his talents as a multi-instrumentalist. Starting off with a solemn debut featuring piano melodies, Chiati seamlessly transitions into different tempoed mixes, integrating various instruments and BPMs into his set. Touching upon various genres, Chiati's mix is musically complex and layered.

Last year we started with the Elite 8 and then moved to the Magnificent 7! With Tesla's unfortunate decline, this power grouping of stocks has shifted once again, now being referred to as the Significant 6! On today's episode of Future Money, Hatem and Ayal provide updates on Microsoft, Meta, Apple, Netflix, Amazon, and Google.The opinions voiced in this material are for general information only and are not intended to provide specific advice or recommendations for any individual. You should consult a financial advisor before making any investment decisions.

2024 will be a year full of innovation and technology! Hatem and Ayal discuss what they are expecting in the year ahead and what specific developments they are most excited for. While providing charts and historical data, the duo dissects some trends about the public's sentiment and adoption of previous new technologies. Watch or Listen to the full episode to find out more!The opinions voiced in this material are for general information only and are not intended to provide specific advice or recommendations for any individual. You should consult a financial advisor before making any investment decisions.

This week, Ayal and Hatem are joined by tech guru Evan Helda to discuss the future of spatial computing and VR. According to them, there's a lot to be excited about in the near future. If you're considering the Apple VisionPros, you don't want to miss this episode!The opinions voiced in this material are for general information only and are not intended to provide specific advice or recommendations for any individual. You should consult a financial advisor before making any investment decisions.

As 2023 comes to a close, Hatem and Ayal discuss their best and works picks of the year. While some companies exceeded expectations, others didn't even come close. You know what they say- Nobody's perfect!The opinions voiced in this material are for general information only and are not intended to provide specific advice or recommendations for any individual. You should consult a financial advisor before making any investment decisions.

Join Imam Tom as he discusses the ruthless Israeli backlash that aims to criminalize dissent from the Israeli PR campaign across the US, and how to fight back against their oppression. We will be joined by Dr. Hatem Bazian, professor of Asian American and Asian Diaspora Studies at UC Berkeley and teacher of Islamic Law at Zaytuna College.

Tesla, Amazon, Apple, Microsoft, Netflix, Meta, Nvidia, and Google! On Today's episode, Hatem and Ayal discuss what they call The Elite 8. Hear what the duo has to say about these 8 companies and why they have made it on such a prestigious list! Follow us on all of our social media platforms: Twitter - https://twitter.com/GerberKawasakiInstagram - https://www.instagram.com/gerberkawasaki/Spotify -https://open.spotify.com/show/6GyluwQ9xIVBjd3Qi7lUxX?si=98e902f0f0df4cfdTikTok - https://www.tiktok.com/@marketswithmiaLinkedIn -https://www.linkedin.com/in/ross-gerber/ Sign up for a free initial consultation at https://gerberkawasaki.com

Join your host Flood with returning guest Richard Hatem for an onslaught of listener questions! Who knows? Maybe your query made the cut! EX V PLANIS https://www.exvplanis.com https://linktr.ee/Exvplanis https://linktr.ee/foldsandfloods https://foldsandfloods.bandcamp.com (GUEST SPOTS) Camera Occulta: https://open.spotify.com/episode/5ypNhSo4vsuwf8v9kU2sV1?si=3af77d94b60c4729 Witch Way From Here: https://open.spotify.com/episode/165j7p92Wv33aupHhaHXGa?si=ee1a025599af4d20 ASTONISHING LEGENDS https://astonishinglegends.com/ HEY STRANGENESS/AARON DEESE https://www.instagram.com/hey_strangeness/ https://www.smalltownmonsters.com/shop/the-texas-dogman-triangle-by-aaron-deese https://www.amazon.com/Dogman-Triangle-Werewolves-Lone-State/dp/B0C5B1TL1P SONNIE SULAK/MOSTLY KNOTTY https://www.mostlyknotty.com/ COLLABORATORS/CONTRIBUTORS ALOREING PODCAST: https://www.instagram.com/aloreingpodcast/ EMPOWERED WITH KRYSTAL E: https://open.spotify.com/show/5fgYMUxI01Eewbk0lNBunC?si=fd7b163140534732          

Pour les vacances d'été, je vous propose de (re)découvrir quelques épisodes passés de Demain N'attend Pas avec des invités particulièrement inspirants.  Après Captain Watson et Jean-Marc Borello, ma dernière rediffusion de l'été sera GHADA HATEM GANTZER, fondatrice de la Maison des Femmes, épisode 53, gynécologue obstétricienne et fondatrice de la Maison des Femmes A 18 ans, Ghada fuit les bombes qui tombent sur le Liban et vient faire ses études de médecine à Paris. Devenue gynécologue obstétricienne, Ghada exerce dans de nombreuses maternités parisiennes, avant de devenir chef de service à la maternité Delafontaine de St Denis.  Là, elle est confrontée à un niveau de précarité et de violence particulièrement élevé : 

1827 beginnt die Irrfahrt einer kleinen Melodie, die in den Ohren der Öffentlichkeit nicht sofort dem richtigen Heimathafen zugeordnet werden kann.

This week's Pack Pride Weekly Podcast is LOADED with guests as Tim Peeler and photographer Greg Hatem join the show live. They just returned from Jim Valvano's induction into the Naismith Hall of Fame and detail their trip for NC State fans. In the second half of the show, Jonathan Paylor joins remotely to discuss his commitment to NC State with Cory Smith. Paylor discusses why he chose the Pack, his role as a recruiter, his fit in Robert Anae's system and much more! This podcast is sponsored by Scott Wood and the Scott Wood Home Lending Team. Reach out to the Wolfpack legend about your home loan at scottwood15.com today!